EU regulators have approved Bayer's Kerendia (finerenone) to treat adults with chronic kidney disease associated with type 2 diabetes, the company announced Monday. The decision comes on the heels of a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, and follows FDA approval of the oral drug for the same indication last year.
Michael Devoy, head of medical affairs and pharmacovigilance at Bayer's pharmaceuticals division, said the EU approval of Kerendia "offers physicians a new path to protect these vulnerable patients by reducing their risk of cardiovascular (CV) events and delaying kidney disease progression." Kerendia works by blocking the mineralocorticoid receptor overactivation thought to contribute to CKD progression and CV damage.
Bayer's filing was supported by data from the Phase III FIDELIO-DKD trial, comparing Kerendia to placebo when added to standard care in around 5700 CKD patients with type 2 diabetes. Results showed that significantly fewer patients in the Kerendia group progressed to a composite endpoint that included a minimum 40% reduction in kidney function, onset of kidney failure, or kidney death.
The drug has also succeeded in the Phase III FIGARO-DKD study of CKD patients with type 2 diabetes. Detailed findings unveiled last year showed that Kerendia significantly reduced the risk of the composite primary endpoint of time to first occurrence of CV death or nonfatal CV events by 13% over a median follow-up of 3.4 years when added to ACE inhibitors or angiotensin receptor blockers. Bayer noted that its treatment has also been submitted for marketing authorisation in China and other countries
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!